Frontage Holdings Corporation, through its subsidiary Frontage Laboratories, has expanded its early phase clinical research capabilities in both the United States and China. This strategic investment enhances support for pharmaceutical and biotech partners, particularly in managing high-volume bioequivalence programs and enabling multi-regional clinical trial execution. The expansion includes a modern 160-bed Phase I clinical unit in Secaucus, New Jersey, and strengthened radiolabeled human AME research capabilities. Additionally, Frontage is increasing its presence in Oncology Phase I trials through new partnerships with hospitals and clinical networks, further broadening its global clinical development solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Frontage Holdings Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE75305) on January 30, 2026, and is solely responsible for the information contained therein.